Mutual Makes Last Plea To High Court For Post-Mensing Case

Law360, New York (November 15, 2012, 6:54 PM EST) -- Mutual Pharmaceutical Co. Inc. stressed Tuesday that if the U.S. Supreme Court did not review a First Circuit ruling over whether generic-drug companies can be targeted for design defect claims, it would allow a decision in direct conflict with its landmark Mensing ruling to stand.

The generics maker is petitioning the high court to take up and reverse the First Circuit's decision to uphold a $23 million award to a woman, Karen Bartlett, who suffered a near-fatal reaction after taking Mutual's drug Sulindac for pain in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.